MONTREAL, Sept. 20, 2012 /CNW Telbec/ - According to Montreal plastic
surgeon Bill Papanastasiou, more than 70% of women who have undergone
breast augmentation surgery claim to have chosen implants that were too
small. "This is because current methods used to simulate the surgery's
outcome are fairly archaic and clearly inadequate in guiding patients
with their choices prior to surgery. Canfield's VECTRA 3D® imaging technology will finally allow Montreal women to choose the size
of implant that suits them and increase their satisfaction level
following breast augmentation."
Offered exclusively at Dr. Papanastasiou's clinic, VECTRA 3D® imaging technology revolutionizes plastic surgery by taking photographs
of the patient and creating a realistic, three-dimensional image that
can be viewed from any angle. This personalized image can be adjusted
according to the different sizes of implant the patient is considering.
"This feature is extremely important because it allows a woman to make
an informed choice and clearly see the implant's effect on her body
image. I also see that the technology often generates a much more open
dialogue between surgeon and patient, leading to results that meet the
patient's expectations," added Dr. Papanastasiou.
Dr. Papanastasiou also believes that this technology will maximize
women's satisfaction level with respect to their surgery. It will
reduce women's insecurity about surgical outcomes and significantly
enhance the decision-making process since only 5% of women interested
in this procedure currently go through with it. Research shows that
women considering breast augmentation wait an average of two years
before going ahead with the surgery.
With more than 25 years of experience as a plastic surgeon, Dr. Bill Papanastasiou is recognized as a North American leader in breast augmentation
surgery. He obtained his degree from McGill University in 1986 and is a
member of and lecturer for various plastic surgery associations. He has
held teaching positions at McGill University and the Université de
Montréal, and is currently associated with St. Mary's Hospital Center.
VECTRA 3D® technology was developed by Canfield Scientific Inc., a New
Jersey-based company, and is distributed in Canada by Allergan.
SOURCE: Dr. V.W. Papanastasiou
For further information:
Bill Papanastasiou, MD, CM, MSc, FRCSC
Toll free: 1-888-248-0208